Piramal Pharma Releases FY26 Earnings Call Recording

Consolidated Revenue FY26: ₹8,869 Crore
Consolidated Profit After Tax FY26: ₹-326 Crore (after impairment loss)

Reader Takeaway: FY26 profit impacted by impairment; strong growth in Consumer Healthcare and ex-US inhalation anesthesia.

Today's Announcement

The conference call recording for Piramal Pharma Limited's audited financial results for the quarter and full year ended March 31, 2026, was made available on its official website on April 29, 2026. Investors can now access management's detailed commentary on the company's performance, following the financial disclosure made on April 17, 2026.

Investor Insights

Access to these call recordings boosts transparency. It helps investors understand management's views on the company's financial results, strategy, and future plans. Listeners can get a closer look at the company's performance after the results were released and find more detail in the Q&A session.

Company Overview

Piramal Pharma is a global pharmaceutical firm. It offers CDMO services through Piramal Pharma Solutions (PPS) and sells branded generics via Complex Hospital Generics (CHG) and India Consumer Healthcare (PCH). PPS drives growth by providing full-service support from drug development to manufacturing. The company became independent in October 2022 after spinning off from Piramal Enterprises Ltd.

What Investors Gain Now

• Investors can now hear management detail Piramal Pharma's FY26 performance and strategy.
• This helps investors better understand how the CDMO and CHG segments performed.
• The recording provides insights into growth areas such as the Kenalog acquisition and sales of inhalation anesthesia outside the U.S.

Key Risks and Regulatory Scrutiny

• Piramal Pharma Solutions received a US FDA warning letter in October 2022 for its Digwal facility, indicating issues with regulatory compliance.
• The company was directed by the Supreme Court in February 2026 to close its Dahej facility over alleged hazardous waste discharge.
• Although SEBI cleared Piramal Pharma of previous non-disclosure claims in November 2024, regulatory attention continues to be a factor.

Competitor Landscape

Piramal Pharma competes with companies like Divi's Laboratories, strong in APIs, and Dr. Reddy's Laboratories, focused on generics. Piramal's strategy emphasizes an integrated CDMO model alongside branded generics. All these companies face similar market conditions, including R&D spending, regulatory challenges, and worldwide demand for medicines.

FY26 Performance Snapshot

• Consolidated Revenue FY26: ₹8,869 Crore. This represents a 3% year-over-year decrease, affected by inventory reductions and slower demand in inhalation anesthesia markets outside the U.S.
• Consolidated Profit After Tax (PAT) FY26: ₹-326 Crore. This figure includes an impairment loss of ₹176 Crore on intangible assets under development.

Future Focus Areas

• Management's view on improving CDMO orders and biopharma funding.
• How the new Kenalog brand performs and growth in inhalation anesthesia sales outside the U.S.
• The Consumer Healthcare business's ongoing progress, boosted by strong brands and online sales.
• Updates on building new capacity and investments, like the Lexington and Riverview projects.
• How net debt is managed, with the company aiming to keep ratios below 3x EBITDA.